Hervé Tilly

Hervé Tilly is an expert in Hematology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Hervé Tilly in the top 1% of experts worldwide for Lymphoma, Lymphoproliferative Disorders and Leukemia. Hervé Tilly has authored 852 publications, the most recent in 2026, and is an investigator in 52 clinical trials, 2 of them ongoing. SLR score: 3,076 (community average: 125). How the SLR is computed.

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 18, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026

Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 852

Citations

Citations: 51 617 1st author: 38 Last author: 88 Unique author: 5

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent. PMID 42802362 — cells, lymphoma, b-cell, lymphoma, aged, b-lymphocytes	Br J Haematol	2026
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma. PMID 42118857 — cells, lymphoma, b-cell, lymphoma, neoplasms, positron emission tomography computed tomography, tumor burden, risk factors, therapeutics, b-lymphocytes	Blood Adv	2026
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. PMID 41979332 — cells, circulating tumor dna, lymphoma, b-cell, lymphoma, neoplasms, predictive value of tests, therapeutics, dna, b-lymphocytes	Blood Adv	2026
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis. PMID 41915772 — lymphoma, follicular, hematology, lymphoma, rituximab, lenalidomide, therapeutics	Blood	2026
FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. PMID 41329901 — lymphoma, follicular, lymphoma, diagnosis, therapeutics	J Clin Oncol Top journal	2025

Clinical Studies 52

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 3 19

Phase 2 15

Phase 1/Phase 2 10

N/A 5

Phase 1 3

By status:

Completed 38

Active not recruiting 7

Terminated 4

Unknown 3

By type:

Interventional 50

Observational 2

By Monocentric/Multicentric:

monocentric 9

multicentric2to4 0

multicentric5to9 4

multicentricup10 39

Main Topics

Hemic and Lymphatic Diseases 44

Immune System Diseases 44

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide in Patients with Follicular Lymphoma 2023-505807-21-00 — lymphoma, follicular, safety, lymphoma, rituximab, lenalidomide, therapeutics	Phase 3	Active not recruiting	2021
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, b-lymphocytes	Phase 2	Active not recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice